HOSPITAL UNIVERSITARIO RUBER
Département
Institut Universitari Dexeus
Barcelona, EspañaPublications en collaboration avec des chercheurs de Institut Universitari Dexeus (8)
2024
-
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial
European Journal of Nuclear Medicine and Molecular Imaging
-
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
Breast Cancer Research and Treatment
-
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 65, Núm. 5, pp. 708-713
2018
-
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
Oncotarget, Vol. 9, Núm. 29, pp. 20617-20630
2016
2015
-
BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors
Melanoma Research, Vol. 25, Núm. 6, pp. 486-495
-
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
Nature Communications, Vol. 6
2012
-
Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: The CLEOPATRE study
Journal of Medical Virology, Vol. 84, Núm. 6, pp. 947-956